Market Newsdesk

NovaBay Pharmaceuticals Reports Third Quarter 2020 Financial Results

• Revenue increased 34% versus prior year
• Avenova^® unit sales set quarterly record
• Exited Q3 with $13.4 million in cash and equivalents
• Regained compliance with NYSE American continued-listing standards
• Launches CelleRx^® Clinical Reset™ into beauty market

Conference call begins at 4:30 p.m. Eastern time today

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay^® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a business update.

“This is an exceptionally exciting time at NovaBay as Avenova unit sales set a new quarterly record and we prepare for the consumer launch of CelleRx Clinical Reset into the beauty market,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. “Product revenue for the quarter increased 34% to $2.2 million from the prior year, with Avenova revenue reaching its highest level since we introduced the direct-to-consumer channel. Online sales of Avenova Direct continued as the fastest-growing channel driven by our successful digital marketing programs featuring lifestyle messaging and increased customer outreach. Sales from our buy-and-sell channel also surged in recent months with the reopening of doctors’ offices across the country.

“Our groundbreaking product CelleRx Clinical Reset creates a new category in skin care,” he added. “Previously we marketed CelleRx to only medical professionals without targeting the consumer market. With a completely new marketing approach for CelleRx Clinical Reset, we intend to leverage our pharmaceutical pedigree in the beauty industry. Clinical Reset disrupts the layer of bacteria that settles and grows on the face, yet is a gentle way to get skin back to a healthy baseline to heal itself and to better absorb skincare products. Clinical Reset’s unveiling will include robust social media and print advertising campaigns targeted directly to the consumer market. Initial sales will be through our newly designed website, cellerx.com.

“We exited the quarter with our strongest cash position since the commercial launch of Avenova in 2015 and have sufficient funds to support current operations through full year 2021, including our enhanced online advertising programs for Avenova and the consumer launch of CelleRx Clinical Reset. We raised $6.4 million in the third quarter from the renegotiation of warrants, which also enabled us to regain compliance with NYSE American continued-listing requirements,” Mr. Hall added. “I’m proud of our many recent accomplishments as they position NovaBay for a bright future.

“We continue actively working with the U.S. Food and Drug Administration (FDA) on a number of items. Our application for Emergency Use Authorization (EUA) to sell the fluorecare^® rapid COVID-19 antibody test is still under review and we have successfully remediated the recent Warning Letter regarding our COVID-19 Avenova marketing. Lastly, we continue to work with the Environmental Protection Agency (EPA) on the inclusion of Avenova on its list of approved disinfectants that kill the COVID-19 virus on hard surfaces,” concluded Mr. Hall.

Third Quarter Financial Results

Net product revenue for the third quarter of 2020 was $2.2 million, a 34% increase from $1.6 million for the third quarter of 2019. Avenova revenue for the third quarter of 2020 was $1.8 million, a 14% increase from $1.6 million for the third quarter of 2019. The increase reflects a higher number of Avenova Direct and buy-and-sell units sold, partially offset by a decrease in the number of units sold through our retail and partner pharmacy channels. The increase in revenue due to unit sales was partially offset by the lower average net selling price associated with Avenova Direct units. Net product revenue for the third quarter of 2020 also includes $0.2 million from the sales of a PhaseOne, a private-label prescription skin and wound care product, with no comparable revenue in the prior-year period.

Gross margin on net product revenue remained unchanged at 75% for the third quarters of 2020 and 2019.

Operating expenses for the third quarter of 2020 were $3.7 million, compared with $2.9 million for the third quarter of 2019. Sales and marketing expenses for the third quarter of 2020 were $1.7 million, compared with $1.5 million for the third quarter of 2019, reflecting an increase in Avenova digital advertising and costs associated with the consumer launch of CelleRx Clinical Reset, partially offset by lower headcount-related costs and lower travel and related expenses due to the impact of COVID-19. General and administrative (G&A) expenses for the third quarter of 2020 were $1.9 million, compared with $1.3 million for the third quarter of 2019, with the increase due to higher legal fees and the cost of the McGovern arbitration. Research and development (R&D) expenses for the third quarter of 2020 were $125,000, compared with $49,000 for the third quarter of 2019.

Operating loss for the third quarter of 2020 was $2.1 million, compared with the operating loss of $1.7 million for the third quarter of 2019.

Non-cash loss on the change of fair value of warrant liability for the third quarter of 2020 was $1.6 million, compared with a non-cash gain of $1.5 million for the third quarter of 2019.

Non-cash gain from adjustments to the fair value of an embedded derivative liability for the third quarter of 2020 was $1,000, compared with $0.7 million for the third quarter of 2019.

Other income, net, for the third quarter of 2020 of $0.4 million is primarily related to qualified expenses incurred under the Paycheck Production Program. This compares with other expense, net, of $0.7 million for the third quarter of 2019, which was due primarily to interest expense recognized on a convertible note that was settled prior to the end of the third quarter of 2020.

The net loss for the third quarter of 2020 was $3.2 million, or $0.08 per share, compared with a net loss for the third quarter of 2019 of $282,000, or $0.01 per share.

Nine Month Financial Results

Net product revenue for the nine months ended September 30, 2020 was $8.0 million, a 66% increase from $4.9 million for the nine months ended September 30, 2019. Gross margin on net product revenue was 61% for the first nine months of 2020, compared with 77% for the first nine months of 2019.

For the nine months ended September 30, 2020, sales and marketing expenses decreased 29% to $4.7 million, G&A expenses of $4.6 million increased 12% and R&D expenses of $0.2 million were relatively unchanged, compared with the nine months ended September 30, 2019.

Operating loss for the first nine months of 2020 was $4.7 million, a 35% improvement from the operating loss of $7.2 million for the first nine months of 2019.

Non-cash loss on the change of fair value of warrant liability for the first nine months of 2020 was $5.2 million, compared with a non-cash gain of $0.9 million for the first nine months of 2019.

Non-cash gain from adjustments to the fair value of an embedded derivative liability for the nine months ended September 30, 2020 was $3,000, compared with $0.4 million for the nine months ended September 30, 2019.

Other income, net, for the first nine months of 2020 was $0.6 million, compared with other expense, net, for the first nine months of 2019 of $1.2 million.

The net loss for the nine months ended September 30, 2020 was $9.3 million, or $0.28 per share, compared with a net loss for the nine months ended September 30, 2019 of $7.0 million, or $0.36 per share.

NovaBay reported cash and cash equivalents of $13.4 million as of September 30, 2020, compared with $6.9 million as of December 31, 2019. The Company raised net proceeds of $5.2 million from the sale of common stock through an ATM agreement during the quarter ended June 30, 2020 and $6.4 million from the renegotiation of warrants during the quarter ended September 30, 2020.

Conference Call

NovaBay management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-677-7731 from within the U.S. or 480-405-6745 from outside the U.S., and requesting the NovaBay Pharmaceuticals call.

A live webcast of the call will be available at http://novabay.com/investors/events and will be archived for 90 days. A replay of the call will be available beginning two hours after the call ends through 11:59 p.m. Eastern time November 26, 2020 by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S., and entering the conference identification number 8439986.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics^®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX^® family of products and the AGANOCIDE^® compounds. The Neutrox family of products includes AVENOVA^® for the eye care market, CELLERX^® for the aesthetic dermatology market and NEUTROPHASE^® for the wound care market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies and current product offerings, potential future product offerings, possible regulatory clearance of any of our products or future products, and any future revenue that may result from selling these products, as well as generally the Company’s expected future financial results. These forward-looking statements are identified by the use of words such as “launch,” “leverage,” “position,” and “continue,” among others. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, the effect on sales and potential reputational damage resulting from decisions or actions taken by regulators, including Warning Letters issued by the FDA, and any other potential regulatory problems that may arise. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay informed on NovaBay’s progress

Like us onFacebook

Follow us onTwitter

Connect with NovaBay onLinkedIn

Visit NovaBay’sWebsite

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email [email protected].

www.Avenova.com

Financial tables to follow

NOVABAY PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except par value amounts)
		September 30,				December 31,
		2020				2019
		(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	13,413			$	6,937
Accounts receivable, net of allowance for doubtful accounts ($0 and $51 at September 30, 2020 and December 31, 2019, respectively)			1,119				1,066
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($194 and $247 at September 30, 2020 and December 31, 2019, respectively)			785				492
Prepaid expenses and other current assets			695				886
Total current assets			16,012				9,381
Operating lease right-of-use assets			518				1,252
Property and equipment, net			76				110
Other assets			476				477
TOTAL ASSETS		$	17,082			$	11,220
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities:
Current liabilities:
Accounts payable		$	796			$	331
Accrued liabilities			1,655				1,778
Operating lease liabilities			400				930
Note payable, related party			104				1,202
Convertible note			—				1,409
Other current liabilities			48				37
Total current liabilities			3,003				5,687
Operating lease liabilities-non-current			197				505
Warrant liability			—				4,055
Total liabilities			3,200				10,247
Stockholders’ equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding at September 30, 2020 and December 31, 2019			—				—
Common stock, $0.01 par value; 75,000 shares and 50,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 41,760 and 27,938 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively			417				279
Additional paid-in capital			147,774				125,718
Accumulated deficit			(134,309	)			(125,024	)
Total stockholders’ equity			13,882				973
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	17,082			$	11,220

NOVABAY PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands except per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2020				2019				2020				2019
Sales:
Product revenue, net		$	2,167			$	1,615			$	8,038			$	4,854
Other revenue, net			3				—				8				41
Total sales, net			2,170				1,615				8,046				4,895
Product cost of goods sold			536				401				3,157				1,145
Gross profit			1,634				1,214				4,889				3,750
Research and development			125				49				249				166
Sales and marketing			1,692				1,544				4,675				6,610
General and administrative			1,879				1,333				4,633				4,136
Total operating expenses			3,696				2,926				9,557				10,912
Operating loss			(2,062	)			(1,712	)			(4,668	)			(7,162	)
Non-cash (loss) gain on changes in fair value of warrant liability			(1,589	)			1,480				(5,224	)			936
Non-cash gain on changes in fair value of embedded derivative liability			1				669				3				423
Other income (expense), net			429				(719	)			605				(1,166	)
Loss before provision for income taxes			(3,221	)			(282	)			(9,284	)			(6,969	)
Provision for income taxes			—				—				(1	)			(3	)
Net loss and comprehensive loss		$	(3,221	)		$	(282	)		$	(9,285	)		$	(6,972	)
Net loss per share attributable to common stockholders (basic)		$	(0.08	)		$	(0.01	)		$	(0.28	)		$	(0.36	)
Net loss per share attributable to common stockholders (diluted)		$	(0.08	)		$	(0.02	)		$	(0.28	)		$	(0.36	)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic)			40,037				23,096				32,614				19,623
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (diluted)			40,067				23,213				32,642				19,623

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005993/en/

NovaBay Contact
Justin Hall

Chief Executive Officer and General Counsel

510-899-8800

[email protected]

Investor Contact
LHA Investor Relations

Jody Cain

310-691-7100

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Optical

MEDIA:

Logo

Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Conference call and webcast today at 4:30 p.m. ET –

SEATTLE–(BUSINESS WIRE)–
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune / inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020.

“Over the last quarter, we built upon the strong momentum created from our option and license agreement with AbbVie for worldwide rights to ALPN-101, by completing an additional private financing with top-tier biotech investors led by Omega Funds, among others,” said Mitch Gold, executive chair and chief executive officer. “These transformative deals have provided us the capital to continue progressing our multiple product candidates through clinical trials.”

Third Quarter 2020 and Subsequent Updates

• Raised $60 Million in a Private Placement. In July, Alpine raised $60 million in gross proceeds through a private placement led by Omega Funds with participation from Avidity Partners, EcoR1 Capital, LLC, Invus Public Equities, L.P., and Samsara BioCapital, among others. Alpine intends to use the net proceeds to fund the development of its clinical and preclinical pipeline as well as for general corporate purposes.
• Preparation for a Phase 2 study of ALPN-101 in systemic lupus erythematosus (SLE). Alpine and AbbVie have agreed on the design of an international Phase 2 study of ALPN-101 in adults with active lupus, anticipated to commence enrollment in the first half of 2021. SLE is a potentially life-threatening, multi-system, chronic autoimmune disease with few approved treatment options. As previously announced, ALPN-101 is the subject of an option and licensing agreement with AbbVie.
• Continued enrollment in NEON-1, a Phase 1 study of ALPN-202 in advanced malignancies. Enrollment is ongoing in the dose escalation portion of NEON-1, a Phase 1, first-in-human monotherapy study of ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor.

Financial Highlights

• As of September 30, 2020, Alpine had cash, cash equivalents, restricted cash, and short-term investments totaling $141.3 million.
• Revenue was $1.9 million for the quarter ended September 30, 2020 compared to $0.3 million in the quarter ended September 30, 2019.
• Research and development expenses for the third quarter ended September 30, 2020 were $6.2 million compared to $9.5 million for the third quarter ended September 30, 2019.
• General and administrative expenses for the third quarter ended September 30, 2020 were $2.7 million compared to $2.5 million for the third quarter ended September 30, 2019.
• Alpine recorded a net loss of $6.1 million and $11.5 million for the third quarters ended September 30, 2020 and 2019, respectively.

As of September 30, 2020, Alpine had $141.3 million in cash, cash equivalents, restricted cash, and short-term investments. Alpine expects that its current cash resources, combined with the potential $75 million in pre-option exercise milestones payable under its option and license agreement with AbbVie, for the development and commercialization of ALPN-101, are sufficient to fund Alpine’s planned operations into 2024, including a planned Phase 2 study of ALPN-101 in systemic lupus erythematosus and the further development of ALPN-202 and ALPN-303.

For additional information regarding Alpine’s planned operations, please refer to “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation – Liquidity and Capital Resources” in Alpine’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which Alpine anticipates filing with the Securities and Exchange Commission on or about November 12, 2020.

Conference Call

Individuals interested in listening to the conference call may do so by dialing (800) 816-3005 for domestic callers, or (857) 770-0069 for international callers, and using the conference ID: 4382628; or from the webcast link in the investor relations section of the company’s website at: www.alpineimmunesciences.com. The recorded webcast will be available for replay for approximately 30 days following the call.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is creating multifunctional immunotherapies via unique protein engineering technologies designed to improve patients’ lives. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

“Secreted Immunomodulatory Proteins”, “SIP”, “Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,” “vIgD” and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the timing of and results from clinical trials and preclinical development activities, clinical and regulatory objectives and the timing thereof, expectations regarding the sufficiency of cash combined with the potential $75 million in pre-option exercise milestones payable under our option and license agreement with AbbVie to fund operations into 2024, the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates, our ability to achieve milestones in our collaboration with AbbVie, the progress and potential of our other ongoing development programs, the timing of our public presentations and potential publication of future clinical data, the efficacy of our clinical trial designs, anticipated enrollment in our clinical trials and the timing thereof, expectations regarding our ongoing collaborations, our anticipated use of the net proceeds from our July 2020 financing and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Alpine Immune Sciences, Inc.
Selected Consolidated Balance Sheet Data
(In thousands)
		September 30, 2020				December 31, 2019
		(unaudited)
Cash and cash equivalents		$	141,075			$	16,123
Short-term investments		—				24,397
Total current assets		142,550				42,302
Total assets		154,033				54,093
Total current liabilities		35,849				8,681
Total stockholders’ equity		67,468				29,474
Total liabilities and stockholders’ equity		154,033				54,093

Consolidated Statement of Operations and Comprehensive Income (Loss) Data
(In thousands, except share and per share amounts)	Three Months Ended September 30,										Nine Months Ended September 30,
	2020					2019					2020					2019
	(unaudited)
Collaboration revenue	$	1,913				$	289				$	3,692				$	856
Operating expenses:
Research and development	6,156					9,532					18,130					30,048
General and administrative	2,728					2,467					7,850					7,365
Total operating expenses	8,884					11,999					25,980					37,413
Loss from operations	(6,971		)			(11,710		)			(22,288		)			(36,557		)
Other income (expense):
Interest expense	(214		)			(66		)			(560		)			(197		)
Interest income	11					301					202					1,042
Other income	1,037					—					1,042					—
Loss before taxes	(6,137		)			(11,475		)			(21,604		)			(35,712		)
Income tax benefit	—					—					6					—
Net loss	$	(6,137	)			$	(11,475	)			$	(21,598	)			$	(35,712	)
Comprehensive income (loss):
Unrealized gain (loss) on investments	—					5					(16		)			37
Unrealized gain (loss) on foreign currency translation	14					(7		)			(35		)			(17		)
Comprehensive loss	$	(6,123	)			$	(11,477	)			$	(21,649	)			$	(35,692	)
Weighted-average shares used to compute basic and diluted net loss per share	22,277,146					18,586,950					19,826,985					18,281,707
Basic and diluted net loss per share	$	(0.28	)			$	(0.62	)			$	(1.09	)			$	(1.95	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005954/en/

Alpine Immune Sciences Inc.

Contact:

Paul Rickey, Chief Financial Officer

Alpine Immune Sciences, Inc.

206-788-4545

[email protected]

Laurence Watts, Managing Director

Gilmartin Group, LLC.

619-916-7620

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Oncology Health Other Science Research Science Pharmaceutical Biotechnology

MEDIA:

Posted on November 12, 2020 4:08 pm

Laird Superfood Appoints Scott McGuire as Chief Operating Officer

Laird Superfood Appoints Scott McGuire as Chief Operating Officer

SISTERS, Ore.–(BUSINESS WIRE)–
Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood”), today announced that Scott McGuire has been appointed Chief Operating Officer, effective November 16, 2020. Mr. McGuire joins Laird Superfood with over 30 years of operational and executive leadership experience in various CPG-related businesses. Jamie Eichman, the Company’s current COO, is transitioning to the new role of Chief Administrative Officer.

“We are thrilled to have Scott join the Laird team,” said Paul Hodge Jr., Co-founder, President and Chief Executive Officer of Laird Superfood. “Throughout his career, Scott has demonstrated a deep understanding of the CPG industry and we believe that his extensive experience in operations, supply chain management and shipping and fulfilment will be instrumental as we build Laird Superfood into a unique platform within several multi-billion dollar addressable markets. We look forward to his leadership.”

Mr. McGuire came to Laird from Bonduelle Fresh Americas, a leader in providing plant based, fresh food products. Most recently, he served as the Chief Supply Chain Officer and held various roles over the last 7 years that included Operations, S&OP, Demand Planning and Execution, Customer Service, Agriculture Purchasing and Operations, and Transportation and Logistics. Before joining Bonduelle Fresh Americas, Mr. McGuire ran his own consulting practice, Joseph Logistics and Supply Chain Solutions, where he provided consulting services for various CPG clients, including Nestlé USA. Prior to that, he served as Nestlé USA’s National Director of Logistics for the company’s Direct-Store Delivery (DSD) division. He also served as Service and Distribution Director for Pepsico’s Frito-Lay Division.

Mr. McGuire holds a bachelor’s degree in Industrial Engineering from Cal Poly San Luis Obispo.

Scott McGuire added, “It is an exciting time at Laird and it is a privilege to be working alongside Paul and his exceptional team. I look forward to applying my experience to drive the company’s growth strategy in the evolving food and beverage industry.”

About Laird Superfood

Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional. The Company’s products are designed to enhance your daily ritual and keep consumers fueled naturally throughout the day. The Company was co-founded in 2015 by the world’s most prolific big-wave surfer, Laird Hamilton. Laird Superfood’s offerings are environmentally conscientious, responsibly tested, and made with real ingredients. Shop all products online at lairdsuperfood.com and join the Laird Superfood community on social media for the latest news and daily doses of inspiration.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005942/en/

ICR

Ashley DeSimone

[email protected]

KEYWORDS: United States North America Oregon New York

INDUSTRY KEYWORDS: Supermarket Retail Other Retail Food/Beverage

MEDIA:

Logo

Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:00 p.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.lyratherapeutics.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The company’s lead product candidate, LYR-210, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS) in patients who have not undergone surgery for the disease. Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease. Beyond CRS, the company believes its XTreo™ platform, comprised of drug administered through a bioresorbable polymeric matrix, has the potential to address other disease areas by precisely, consistently and locally delivering medicines for sustained periods with a single administration.

For more information, please visit www.lyratherapeutics.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company’s lead product candidate LYR-210 and its cash balance for fiscal year ended December 31, 2020. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the fact that the company has incurred significant losses since inception and expects to incur losses for the foreseeable future; the company’s need for additional funding, which may not be available; the company’s limited operating history; the fact that the company has no approved products; the fact that the company’s product candidates are in various stages of development; the fact that the company may not be successful in its efforts to identify and successfully commercialize its product candidates; the fact that clinical trials required for the company’s product candidates are expensive and time-consuming, and their outcome is uncertain; the fact that the FDA may not conclude that certain of the company’s product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway; the company’s inability to obtain required regulatory approvals; effects of recently enacted and future legislation; the possibility of system failures or security breaches; effects of significant competition; the fact that the successful commercialization of the company’s product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies; failure to achieve market acceptance; product liability lawsuits; the fact that the company relies on third parties for the manufacture of materials for its research programs, pre-clinical studies and clinical trials; the company’s reliance on third parties to conduct its preclinical studies and clinical trials; the company’s inability to succeed in establishing and maintaining collaborative relationships; the company’s reliance on certain suppliers critical to its production; failure to obtain and maintain or adequately protect the company’s intellectual property rights; failure to retain key personnel or to recruit qualified personnel; difficulties in managing the company’s growth; effects of natural disasters; the fact that the global pandemic caused by COVID-19 could adversely impact the company’s business and operations, including the company’s clinical trials; the fact that the price of the company’s common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company and any securities class action litigation. These and other important factors discussed under the caption “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the SEC on November 10, 2020 and its other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005919/en/

Investor Contact:

Laurence Watts

619-916-7620

[email protected]

Media Contact:

Kathryn Morris

914-204-6412

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Pharmaceutical

MEDIA:

Posted on November 12, 2020 4:08 pm

TransAct Technologies to Present Virtually and Host 1×1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18th & 19th

TransAct Technologies to Present Virtually and Host 1×1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18^th & 19^th

HAMDEN, Conn.–(BUSINESS WIRE)–TransAct Technologies Incorporated (Nasdaq: TACT), a global leader in software-driven technology and printing solutions for high-growth markets, today announced Bart Shuldman, Chairman and Chief Executive Officer will participate in the virtual Southwest IDEAS Investor Conference on November 18, 2020. TransAct Technologies’ presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18^th. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants, in the investor relations section of the Company’s website: visit www.transact-tech.com, and on the IDEAS conference website: www.IDEASconferences.com.

About IDEAS Investor Conferences

The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. Unlike traditional bank-sponsored events, IDEAS Investor Conferences are “Sponsored BY the Buyside FOR the Buyside” and for the benefit of regional investment communities. Conference sponsors collectively have more than $200 billion in assets under management and include: Adirondack Research and Management, Allianz Global Investors: NFJ Investment Group, Ariel Investments, Aristotle Capital Boston, Barrow Hanley Mewhinney & Strauss, BMO Global Asset Management, Constitution Research & Management, Inc., Fidelity Investments, First Wilshire Securities Management, Inc., Gamco Investors, Granahan Investment Management, Great Lakes Advisors, Greenbrier Partners Capital Management, LLC, GRT Capital Partners, LLC, Hodges Capital Management, Ironwood Investment Management, Keeley Teton Advisors, Luther King Capital Management, Marble Harbor Investment Counsel, Perritt Capital Management, Punch & Associates, Westwood Holdings Group, Inc., and William Harris Investors.

The IDEAS Investor Conferences are held annually in Boston, Chicago and Dallas and are produced by Three Part Advisors, LLC. Additional information about the events can be located at www.IDEASconferences.com.

If interested in participating or learning more about the IDEAS conferences, please contact Lacey Wesley at (817) 769 -2373 or [email protected].

About TransAct Technologies Incorporated

TransAct Technologies Incorporated is a global leader in developing software-driven technology and printing solutions for high-growth markets including restaurant solutions, POS automation, casino and gaming, and oil and gas. The Company’s solutions are designed from the ground up based on customer requirements and are sold under the BOHA!™, AccuDate™, EPICENTRAL®, Epic®, Ithaca® and Printrex® brands. TransAct has sold over 3.3 million printers and terminals around the world and is committed to providing world-class service, spare parts and accessories to support its installed product base. Through the TransAct Services Group, the Company also provides customers with a complete range of supplies and consumable items both online at http://www.transactsupplies.com and through its direct sales team. TransAct is headquartered in Hamden, CT. For more information, please visit http://www.transact-tech.com or call (203) 859-6800.

BOHA! is a trademark of TRANSACT Technologies Incorporated. ©2020 TRANSACT Technologies Incorporated. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005886/en/

Investor Contact:

Steve DeMartino

President and Chief Financial Officer

TransAct Technologies Incorporated

203-859-6810

Michael Bowen

ICR, Inc.

[email protected]

203-682-8299

Marc P. Griffin

ICR, Inc.

[email protected]

646-277-1290

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Software Entertainment Restaurant/Bar Oil/Gas Data Management Energy Technology General Entertainment Other Entertainment Retail Electronic Games Casino/Gaming

MEDIA:

Posted on November 12, 2020 4:08 pm

CuriosityStream Announces Third Quarter 2020 Financial Results

CuriosityStream Announces Third Quarter 2020 Financial Results

• Third quarter 2020 revenue of $8.7 million, up 83% year-over-year
• Gross margin increases to 61% year-over-year from 59% in Q3 2019
• Strengthens executive team with key industry veterans  

SILVER SPRING, Md.–(BUSINESS WIRE)–
CuriosityStream Inc. (NASDAQ: CURI), a global factual entertainment company, today announced its financial results for the third quarter ending September 30, 2020.

“We had a strong third quarter, with an 83% year-over-year increase in revenue and growth across all lines of business. Our subscribers more than doubled year over year, with notable increases in annual plans and international subscriptions, as we continued to offer fresh and unique original content every week,” said Clint Stinchcomb, President & CEO. “We continue to be on a three-year trajectory of doubling annual revenue with large recurring revenues and high gross margins as we drive growth across the entire business.”

Third Quarter 2020 Financial Results

• Revenue of $8.7 million, up from $4.8 million in the third quarter of 2019;
• Total paying subscribers of approximately 13 million, up 108% year-over-year;
• Gross margin increased 200 basis points year-over-year to 61%;
• Operating loss was $(6.8) million compared to operating loss of $(10.1) million in the third quarter of 2019;
• EBITDA was $(6.7) million compared to EBITDA of $(10.0) million in the third quarter of 2019;
• GAAP net loss was $(6.7) million and GAAP basic and diluted net loss per share was $(0.56);
• Sources of cash totaled $23.3 million as of September 30, 2020.

Business Highlights

• Closed business combination with Software Acquisition Group, Inc. (NASDAQ: SAQN) and began trading on the NASDAQ exchange under ticker symbol “CURI” on October 15, 2020, becoming the first streaming media company devoted to factual entertainment to go public;
• Named international media executive Bakori Davis to the newly created position of Managing Director and Head of International Distribution;
• Named industry veteran Nate Stamos VP of Brand Partnerships;
• Appointed entertainment and cable industry pioneer Matthew Blank, former Chairman and CEO of Showtime Networks, Inc., to CuriosityStream’s Board of Directors;
• Announced several brand-defining original series including MY WILD BACKYARD,the third season of 4th AND FOREVER, DOUG TO THE RESCUE and NATURE THROUGH HER EYES;
• In a separate release today, CuriosityStream announced the November 19th, 2020 world premiere of the original new series BEYOND THE SPOTLIGHT from Executive Producer Leonardo DiCaprio and Appian Way Productions and Stephen David Entertainment. First episodes feature Shaquille O’Neal, Kristen Bell and Samuel L. Jackson and LaTanya Richardson Jackson.

Financial Outlook

For the fourth quarter of 2020, CuriosityStream currently expects the following:

• Revenue of at least $11.3 million, or 69% year-over-year growth

For the full year 2020 & 2021, CuriosityStream currently expects the following:

• 2020 revenue of at least $39.5 million, or 119% year-over-year growth
• 2021 revenue of at least $71 million, or 80% year-over-year growth

Conference Call Information

CuriosityStream will host a Q&A conference call today to discuss the Company’s Q3 2020 results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the call will be available on the CuriosityStream Investor Relations website at https://investors.curiositystream.com. A live dial-in is available domestically at (800) 585-8367 or internationally at (416) 621-4642, with passcode 9085595.

An audio replay of the conference call will be available for two weeks following the call and available on the CuriosityStream Investor Relations website at https://investors.curiositystream.com.

Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, CuriosityStream’s expectations or predictions of future financial or business performance or conditions and the information under the heading “Financial Outlook” in this press release. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “predicts” or “intends” or similar expressions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed under “Risk Factors” in the Definitive Proxy Statement on Schedule 14A filed on September 22, 2020, and in CuriosityStream’s other SEC filings. These risk factors will be important to consider in determining future results and should be reviewed in their entirety. Forward-looking statements are based on the current belief of the management of CuriosityStream, based on currently available information, as to the outcome and timing of future events, and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made, and CuriosityStream is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that CuriosityStream has filed or will file from time to time with the SEC.

In addition to factors previously disclosed in CuriosityStream’s reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: (i) the effect of the merger on CuriosityStream’s business relationships, operating results, and business generally; (ii) failure to realize the benefits expected from the merger; (iii) risks that the merger disrupts CuriosityStream’s current plans and operations and potential difficulties in CuriosityStream’s employee retention as a result of the merger; (iv) the effects of pending and future legislation; (viii) risks related to CuriosityStream’s limited operating history; (ix) the amount of the costs, fees, expenses and other charges related to the merger; (x) risks of the internet, online commerce and media industry; (xi) the highly competitive nature of the internet, online commerce and media industry and CuriosityStream’s ability to compete therein; (xii) litigation, complaints, and/or adverse publicity; (xiii) the ability to meet Nasdaq’s listing standards and (ix) privacy and data protection laws, privacy or data breaches, or the loss of data.

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared in accordance with GAAP, we present EBITDA in this press release. Our use of non-GAAP financial measures has limitations as an analytical tool, and these measures should not be considered in isolation or as a substitute for analysis of financial results as reported under GAAP.

We use this non-GAAP financial measure in conjunction with financial measures prepared in accordance with GAAP for planning purposes, including in the preparation of our annual operating budget, as a measure of our core operating results and the effectiveness of our business strategy, and in evaluating our financial performance. This measure provides consistency and comparability with past financial performance, facilitates period-to-period comparisons of core operating results, and also facilitates comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results. In addition, EBITDA is widely used by investors and securities analysts to measure a company’s operating performance. We exclude the following items from one or more of our non-GAAP financial measures: other income, income taxes, and depreciation and amortization.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, (1) stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy, (2) although depreciation and amortization expense are non-cash charges, the assets subject to depreciation and amortization may have to be replaced in the future, and EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements, and (3) EBITDA does not reflect: (a) changes in, or cash requirements for, our working capital needs; (b) or tax payments that may represent a reduction in cash available to us. The non-GAAP measure we use may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures. A reconciliation of these non-GAAP measures has been provided in the financial statement tables included in this press release and investors are encouraged to review the reconciliation.

About CuriosityStream

Launched by media visionary John Hendricks, CuriosityStream is one of the world’s leading global factual streaming services and media companies. Our documentary series and features cover every topic from space exploration to adventure to the secret life of pets, empowering viewers of all ages to fuel their passions and explore new ones. With thousands of titles, many in Ultra HD 4K, including exclusive originals, CuriosityStream features stunning visuals and unrivaled storytelling to demystify science, nature, history, technology, society, and lifestyle. CuriosityStream programming is available worldwide to watch on TV, desktop, mobile and tablets. Find us on Roku, Apple TV Channels and Apple TV, Xbox One, Amazon Fire TV, Google Chromecast, iOS and Android, as well as Amazon Prime Video Channels, YouTube TV, Sling TV, DISH, Comcast Xfinity on Demand, Cox Communications, Altice USA, Suddenlink, T- Mobile, Frndly TV, Vidgo, Sony, LG, Samsung and VIZIO smart TVs, Liberty Global, Com Hem, MultiChoice, StarHub TV, Totalplay, Millicom, Okko, Gazprom and other global distribution partners and platforms. For more information, visit CuriosityStream.com.

CuriosityStream Inc. Unaudited Statements of Operations (in thousands, except for per share data)
		For the three months ended September 30,								For the nine months ended September 30,
		2020				2019				2020				2019
Revenues		$	8,744			$	4,791			$	28,260			$	11,336
Operating expenses
Cost of revenues			3,411				1,946				10,748				4,384
Advertising and marketing			7,800				9,410				28,673				26,124
General and administrative			4,286				3,539				12,191				10,388
			15,497				14,895				51,612				40,896
Operating loss			(6,753	)			(10,104	)			(23,352	)			(29,560	)
Other income (expense)
Interest and other income (expense)			101				475				519				1,719
Loss before income taxes			(6,652	)			(9,629	)			(22,833	)			(27,841	)
Provision for income taxes			41				30				118				103
Net loss		$	(6,693	)		$	(9,659	)		$	(22,951	)		$	(27,944	)
Less preferred dividends and accretion of issuance costs (Note 6)			(4,523	)			(4,059	)			(13,114	)			(11,725	)
Net loss attributable to common stockholders		$	(11,216	)		$	(13,718	)		$	(36,065	)		$	(39,669	)
Net loss per share attributable to common stockholders
Basic and diluted			(0.56	)			(0.69	)			(1.80	)			(1.98	)
Weighted average number of common shares outstanding

CuriosityStream Inc. Balance Sheets (in thousands, except par value)
		September 30,				December 31,
		2020				2019
		(unaudited)
Assets
Current assets
Cash and cash equivalents		$	3,374			$	8,819
Restricted cash			5,000				–
Short-term investments			12,114				35,525
Accounts receivable			5,800				1,777
Other current assets			2,951				2,460
Total current assets			29,239				48,581
Investments			2,770				15,654
Property and equipment, net			1,358				1,451
Content assets, net			23,826				16,627
Other assets			2,790				151
Total assets		$	59,983			$	82,464
Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)
Current liabilities
Current content liabilities		$	2,165			$	3,306
Accounts payable			2,323				5,245
Accrued expenses and other liabilities			2,542				2,266
Deferred revenue			8,885				7,101
Line of credit			950				–
Total current liabilities			16,865				17,918
Non-current deferred rent liability			905				824
Total liabilities			17,770				18,742
Commitments and contingencies
Redeemable convertible preferred stock, $0.01 par value, 30,000 shares authorized at September 30, 2020 and December 31, 2019; aggregate liquidation preference of $175,104 and $162,514 as of September 30, 2020 and December 31, 2019, respectively; 14,557 shares issued and outstanding at September 30, 2020 and December 31, 2019			168,288				155,174
Stockholders’ equity (deficit)
Class A Common stock, $0.01 par value – 50,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 14 and nil shares issued and outstanding at September 30, 2020 and December 31, 2019 respectively			–				–
Class B Common stock, $0.01 par value – 25,000 shares authorized at September 30, 2020 and December 31, 2019; 20,000 shares issued and outstanding at September 30, 2020 and December 31, 2019			200				200
Additional paid-in capital			–				–
Accumulated other comprehensive income			55				189
Accumulated deficit			(126,330	)			(91,841	)
Total stockholders’ equity (deficit)			(126,075	)			(91,452	)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)		$	59,983			$	82,464

CuriosityStream Inc. Unaudited Statements of Cash Flows (in thousands)
		For the nine months ended September 30,
		2020				2019
Cash flows from operating activities
Net loss		$	(22,951	)		$	(27,944	)
Adjustments to reconcile net loss to net cash used in operating activities
Additions to content assets			(14,004	)			(12,029	)
Change in content liabilities			(1,141	)			1,241
Amortization of content assets			6,805				2,441
Amortization, depreciation and accretion			399				64
Stock-based compensation			1,540				671
Changes in operating assets and liabilities
Accounts receivable			(4,023	)			(244	)
Other assets			(773	)			945
Accounts payable			(3,263	)			1,460
Accrued expenses and other liabilities			124				407
Deferred revenue			1,784				1,253
Net cash used in operating activities			(35,503	)			(31,735	)
Cash flows from investing activities
Purchases of property and equipment			(299	)			(590	)
Sales of investments			39,744				30,309
Maturities of investments			8,500				7,947
Purchase of investments			(12,227	)			(48,243	)
Net cash provided by (used in) investing activities			35,718				(10,577	)
Cash flows from financing activities
Exercise of stock options			36				–
Borrowings on line of credit			8,250				–
Repayments on line of credit			(7,300	)			–
Payment of offering costs			(1,646	)			–
Net cash used in financing activities			(660	)			–
Net decrease in cash, cash equivalents and restricted cash			(445	)			(42,312	)
Cash, cash equivalents and restricted cash, beginning of period			8,819				62,516
Cash, cash equivalents and restricted cash, end of period		$	8,374			$	20,204
Supplemental schedule of non-cash financing activities:
Preferred dividends and accretion of issuance costs		$	13,114			$	11,725

Reconciliation of GAAP Financial Metrics to Non-GAAP
(in thousands)
(unaudited)
Reconciliation of Net Loss to EBITDA
	For the three months ended September 30,								For the nine months ended September 30,
		2020				2019				2020				2019
Net loss	$	(6,693	)		$	(9,659	)		$	(22,951	)		$	(27,944	)
Other income		(101	)			(475	)			(519	)			(1,719	)
Income taxes		41				30				118				103
Depreciation and amortization		83				63				256				170
EBITDA	$	(6,670	)		$	(10,041	)		$	(23,096	)		$	(29,390	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20201112006054/en/

CuriosityStream Public Relations:

Vanessa Gillon

[email protected]

CuriosityStream Investor Relations:

Denise Garcia

[email protected]

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Film & Motion Pictures Online General Entertainment Entertainment TV and Radio

MEDIA:

Logo